Clinical Trial

A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors

Study acronym: BRIDGE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a observational study aimed at evaluating miRNA 371a-3p (miRNA 371) as a specific marker for presence or absence of clinically detectable viable germ cell malignancy.
Trial Details
NCT Number NCT07453082
Lead Sponsor Fondazione del Piemonte per l'Oncologia
Conditions Testicular Germ Cell Tumor
Enrollment 100 participants
Start Date 2021-07-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05